Eli Lilly and Company

Novo Nordisk A/S

China has entered the race in the market of weight loss drugs: several companies from China have presented their products that may become competitors to Ozempic, Mounjaro and other hits from Novo Nordisk and Eli Lilly. The first of these received regulatory approval in June. In general, Chinese biotech has survived the prolonged "nuclear winter" and is now actively developing. What should an investor know about it?

#: 1

The end of nuclear winter and tens of percent growth: how China is growing its pharma giants